Cardiovascular disease is the leading cause of mortality and accounts for one-third of global deaths. "We expect it to remain a dominant therapy for the next 10-15 years and gain 300-400bps share in the same period," says Bansi Desai, Institutional Research Analyst, HDFC Securities. Among the listed players, HDFC Securities find potential in Lupin, Glenmark, JB Chemicals and Cipla. HDFC …
